Human Reproduction, Vol. 15, No. 6, 1305-1310,
June 2000
© 2000 European Society of Human Reproduction and Embryology
A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation
1 City West IVF, City West House, 12 Caroline Street, Westmead, NSW, Australia 2145 and 2 Fertility Associates, Ascot Integrated Hospital, 90 Greenlane Road East, Remuera, Auckland, New Zealand
A randomized, controlled, double-blind, double-dummy, phase III clinical trial was conducted in 84 women to compare the efficacy of a s.c. injection of 250 µg recombinant human chorionic gonadotrophin (rHCG; Ovidrel®) to an i.m. injection of 5000 IU urinary HCG (uHCG; Profasi®) in inducing folliculogenesis, resumption of oocyte meiosis and luteinization after ovulation induction with recombinant follicle stimulating hormone (Gonal-F®). The study primary endpoint was comparison of the number of oocytes retrieved per patient receiving either compound. Secondary comparisons included the number of oocytes retrieved per follicles aspirated; the number of mature oocytes; normally fertilized oocytes; and cleaved embryos. There were no statistically significant differences between groups for the primary endpoint (mean ± SD oocytes retrieved 10.8 ± 4.5 for rHCG versus 10.3 ± 5.1 for uHCG) or each of the secondary endpoints except for increased concentrations of progesterone 6–7 days after rHCG administration (353.2 ± 215.1 versus 234.1 ± 129.4 nmol/l; P < 0.004) and for HCG during the luteal phase following rHCG (P < 0.02). There were also no significant side-effects for either drug. Since the confidence intervals for the difference of the number of oocytes retrieved between the two treatment groups were within the bounds defined by the multi-trial protocol equivalence between rHCG and uHCG could be declared.
Key words: assisted reproduction treatment/ovulation induction/recombinant HCG/recombinant FSH/urinary HCG
3 To whom correspondence should be addressed at: City West IVF, 12 Caroline Street, Westmead, NSW, Australia 2145.E-mail: jtyler{at}ivf.com.au
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Al-Inany, M. A. Aboulghar, R. T. Mansour, and M. Proctor Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception Hum. Reprod., August 1, 2005; 20(8): 2061 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. W. Chan, E. H. Y. Ng, O. S. Tang, W. S. B. Yeung, E. Y. L. Lau, and P. C. Ho A Prospective, Randomized, Double-Blind Study to Compare Two Doses of Recombinant Human Chorionic Gonadotropin in Inducing Final Oocyte Maturity and the Hormonal Profile during the Luteal Phase J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3933 - 3938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Arce, A. Nyboe Andersen, and J. Collins Resolving methodological and clinical issues in the design of efficacy trials in assisted reproductive technologies: a mini-review Hum. Reprod., July 1, 2005; 20(7): 1757 - 1771. [Abstract] [Full Text] [PDF]
|
|